11 completed, 1 active not recruiting, 1 not yet recruiting. 13 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow HIV Seropositivity: new trials by email Literature Review of HIV Seropositivity trials Research Report on HIV Seropositivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy - ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1 / Phase 2 | Not yet recruiting | David Simon | 8 | 2025-01-01 | 2024-09-19 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients Mefloquine, Sulphadoxine-Pyrimethamine - Malaria in Pregnant HIV + Patients | Phase 1 | Completed | ORIYOMI OMOTOYOSI AKINYOTU | 142 | 2015-09-01 | 2017-12-11 |
| A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients Sulphadoxine-pyrimethamine, Azithromycin - Malaria, Pregnant | Phase 1 | Completed | University of Ibadan | 140 | 2015-09-01 | 2017-12-11 |
| A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. AGS-004 - HIV Seropositivity, Acquired Immunodeficiency Syndrome | Phase 1 / Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 10 | 2006-09-01 | 2009-01-29 |
| Adopting and Demonstrating the Adaptation of Prevention Techniques: Community PROMISE PLUS Community PROMISE - HIV Prevention, STD Prevention | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 574 | 2006-07-01 | 2012-04-13 |
| Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP - HIV | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 17 | 2005-12-21 | 2017-07-02 |
| Safety and Acceptability of Carraguard® in HIV Positive Women and Men Carraguard (PC-515) - HIV Infections | Phase 1 | Completed | Population Council | 60 | 2002-06-01 | 2017-08-14 |
| A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects Ampligen - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2021-11-03 | |
| A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2021-11-03 | |
| A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes Zidovudine, Aldesleukin - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2021-11-04 | |
| Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2021-11-04 | |
| Safety and Tolerability of the Vaginal Gel PRO 2000/5 PRO 2000 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2008-07-30 |
HIV Infections (6) · Acquired Immunodeficiency Syndrome (4) · AIDS-Related Complex (2) · Malaria (2) · Hypersensitivity, Delayed (1) · Latent Tuberculosis (1) · Sexual Abstinence (1) · Ulcer (1) · Vasculitis (1)
Blood-Borne Infections (13) · Communicable Diseases (13) · Genital Diseases (13) · Immune System Diseases (13) · Immunologic Deficiency Syndromes (13) · Infections (13) · Lentivirus Infections (13) · RNA Virus Infections (13) · Retroviridae Infections (13) · Sexually Transmitted Diseases (13) · Sexually Transmitted Diseases, Viral (13) · Urogenital Diseases (13) · Virus Diseases (13) · HIV Infections (7) · Slow Virus Diseases (4)
VaxSyn HIV-1 (gp160) vaccine (2) · fanasil, pyrimethamine drug combination (2) · Azithromycin (1) · Isoniazid (1) · Mefloquine (1) · PRO 2000 (1) · Zidovudine (1) · aldesleukin (1) · poly(I).poly(c12,U) (1) · rifapentine (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Centers for Disease Control and Prevention (1) · David Simon (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · ORIYOMI OMOTOYOSI AKINYOTU (1) · Population Council (1) · The Aurum Institute NPC (1) · University of Ibadan (1)
United States (7) · Nigeria (2) · South Africa (2) · Canada (1)
Dr Vaneshree Govender (1) · Gita Ramjee, Ph.D (1) · Janneke van de Wijgert, Ph.D. (1) · Jean-Pierre Routy, MD (1) · Jennifer S Galbraith (1) · K Weinhold (1) · Katzenstein DA (1) · Ken Mayer (1) · M Ho (1) · Salim Abdool Karim (1) · Valentine F (1)
PMID 39324693, PMID 12631091, PMID 18193495, PMID 18528326, PMID 2161532, PMID 21859691, PMID 23482645, PMID 29719927, PMID 32291416, PMID 32855422, PMID 34347960, PMID 34501224, PMID 36109639, PMID 36927642, PMID 37748491, PMID 38182404, PMID 38381673